RXi Pharmaceuticals Appoints H. Paul Dorman and Curtis Lockshin, Ph.D. to Board of Directors

  RXi Pharmaceuticals Appoints H. Paul Dorman and Curtis Lockshin, Ph.D. to
  Board of Directors

Business Wire

WESTBOROUGH, Mass. -- April 22, 2013

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused
on discovering, developing and commercializing innovative therapies addressing
major unmet medical needs using RNA-targeted technologies, today announced
that H. Paul Dorman and Curtis Lockshin, Ph.D. have been appointed to the
Company’s Board of Directors. Mr. Dorman and Dr. Lockshin both bring
significant industry experience that will be instrumental to supporting RXi’s
growth and development initiatives.

Mr. Dorman brings nearly three decades of executive experience in the
pharmaceutical industry with Johnson & Johnson and Baxter, in various
leadership roles, to RXi. He currently serves as Chairman and CEO of DFB
Pharmaceuticals, a Fort Worth, TX based holding company that, over the last 20
years, has successfully invested in and operated multiple pharmaceutical
businesses. In that role, he acquired several companies, three of which were
turned around to profitability, from Chapter 11 status at acquisition, and
later sold to a large, multi-national, public corporation. He holds a Bachelor
of Science degree in Mechanical Engineering from Tulane University and a Juris
Doctor of Law from Loyola University. “Mr. Dorman is one of the remarkable
icons in the healthcare industry and we are thrilled to have him join our
Board,” said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals.
He added that, “Paul’s experience and network in both the large and small
pharma world, as well as his wisdom in leading companies to success, will be
major contributing factors to the RXi Board of Directors and the growth of our
Company.”

Dr. Lockshin comes to RXi providing exceptional industry insight and
functional, hands-on experience. Most recently, he has been an Independent
Pharmaceutical & Life Sciences Consultant for OPKO Health, Inc. Prior to this
role, Dr. Lockshin served as Vice President, Corporate R&D Initiatives for
OPKO Health, Inc., with operational responsibilities inside several of OPKO's
R&D units. He currently serves as a Director of the Ruth K. Broad Biomedical
Research Foundation, a Duke University Support Corporation. He previously
served as a Director of Sorrento Therapeutics and Winston Pharmaceuticals. He
initially began his career as a scientist with Sepracor and eventually became
the research director responsible for the strategy and operations of
Sepracor's new leads initiative. He is a Co-Inventor on several U.S. patents
and applications, covering pharmaceuticals, biomaterials, and optics for
remote biochemical sensing. Dr. Lockshin holds a Ph.D. in Biological Chemistry
from the Massachusetts Institute of Technology. “Dr. Lockshin has an
impressive career track record in research and development of new drugs”,
commented Dr. Geert Cauwenbergh. “With RXi Pharmaceuticals in the midst of a
game changing drug in development with RXI-109 for dermal scarring, Curt will
provide valuable insights into the development of our drugs. With Paul Dorman
and Curt Lockshin joining our current Board members Bob Bitterman and Keith
Brownlie, RXi Pharmaceuticals has a well rounded Board of Directors with an
appropriate balance of all key elements needed for success.”

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused
on discovering, developing and commercializing innovative therapies based on
its proprietary, self-delivering RNAi platform. Therapeutics that use RNA
interference, or “RNAi,” have great promise because of their ability to
down-regulate, the expression of a specific gene that may be over-expressed in
a disease condition. Building on the pioneering work of scientific founder and
Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board,
RXi’s first RNAi product candidate, RXI-109, which targets CTGF, entered into
human clinical development in June 2012. For more information, please visit
www.rxipharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to, statements about future expectations, planned and
future development of RXi Pharmaceuticals Corporation’s products and
technologies. Forward-looking statements about expectations and development
plans of RXi’s products involve significant risks, and uncertainties: risks
that RXi may not be able to successfully develop its candidates, or that
development of RNAi-based therapeutics may be delayed or not proceed as
planned, or that we may not develop any RNAi-based product; risks that the
development process for our product candidates may be delayed, risks related
to development and commercialization of products by our competitors, risks
related to our ability to control timing and terms of collaborations with
third parties, and the possibility that other companies or organizations may
assert patent rights preventing us from developing our products. Actual
results may differ from those contemplated by these forward-looking
statements. RXi does not undertake to update forward-looking statements to
reflect a change in its views, events or circumstances that occur after the
date of this release.

Contact:

RXi Pharmaceuticals Corporation
Tamara McGrillen, 508-929-3646
tmcgrillen@rxipharma.com